Advanced Enzyme Technologies Limited announced its financial results for the first quarter ended June 30, 2026. Revenue from operations saw a 2% increase year-on-year, reaching ₹1,898 million. The company highlighted strong performance in its Bio-Processing segment and provided an outlook for business growth in key segments through 2026-27.
Advanced Enzyme Technologies Reports Q1 FY27 Financials
Advanced Enzyme Technologies Limited has released its unaudited financial results for the first quarter of the fiscal year 2027, which concluded on June 30, 2026. The company reported a consolidated revenue from operations of ₹1,898 million, marking a 2% increase compared to ₹1,859 million in the same quarter of the previous fiscal year (Q1 FY26). Sequentially, revenue saw a 7% de-growth from ₹2,034 million in Q4 FY26.
Profitability and Margins
Consolidated EBITDA for Q1 FY27 stood at ₹510 million, a 10% decrease year-on-year from ₹564 million in Q1 FY26, and a 19% decrease quarter-on-quarter from ₹632 million in Q4 FY26. Profit before tax (PBT) was reported at ₹535 million, down 3% year-on-year and 10% quarter-on-quarter. Profit after tax (PAT) was ₹386 million, a 5% decrease year-on-year and a 15% decrease quarter-on-quarter. The EBITDA margin for the quarter was 27%, with PAT margin at 20%.
Segmental Performance Review
The Human Nutrition segment experienced a 7% year-on-year decline in revenue to ₹1,139 million in Q1 FY27, primarily due to lower sales in the Pharma/API business. The Animal Nutrition segment saw a 3% year-on-year decrease to ₹252 million. In contrast, the Bio-Processing segment showed robust growth, with revenue increasing by 30% year-on-year to ₹306 million. The Food business within this segment grew by 51% year-on-year. The Specialized Manufacturing segment reported a significant 41% year-on-year increase in revenue to ₹200 million.
Geographical Revenue Breakdown
Domestic sales accounted for 49% of the revenue in Q1 FY27, amounting to ₹937 million, a 4% decrease year-on-year. International sales represented 51% of the revenue, growing by 9% year-on-year to ₹961 million. Europe saw a significant growth of 44%, and Asia (ex-India) grew by 37%, while Americas declined by 3%.
Outlook for 2026-27
Looking ahead to the 2026-27 fiscal year, Advanced Enzymes is committed to strengthening its business model with a focus on its core segments: Human Nutrition, Animal Nutrition, and Bio-Processing. The company plans to expand its product portfolio, particularly in probiotics, and leverage its existing infrastructure for growth. The Human Nutrition segment is expected to be a key growth driver, with the launch of its nutraceutical brand, Wellfa, in India. The company also intends to explore strategic acquisition opportunities to enhance its market presence and product offerings.
Source: BSE
